PE20201346A1 - Constructos de fusion de anticuerpos que se acoplan a celulas nk - Google Patents
Constructos de fusion de anticuerpos que se acoplan a celulas nkInfo
- Publication number
- PE20201346A1 PE20201346A1 PE2020001584A PE2020001584A PE20201346A1 PE 20201346 A1 PE20201346 A1 PE 20201346A1 PE 2020001584 A PE2020001584 A PE 2020001584A PE 2020001584 A PE2020001584 A PE 2020001584A PE 20201346 A1 PE20201346 A1 PE 20201346A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- cells
- cd16a
- coupled
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167384 | 2018-04-13 | ||
| EP18167385 | 2018-04-13 | ||
| EP18190662 | 2018-08-24 | ||
| EP18190661 | 2018-08-24 | ||
| PCT/IB2019/053040 WO2019198051A2 (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201346A1 true PE20201346A1 (es) | 2020-11-25 |
Family
ID=66625219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001584A PE20201346A1 (es) | 2018-04-13 | 2019-04-12 | Constructos de fusion de anticuerpos que se acoplan a celulas nk |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11001633B2 (enExample) |
| EP (1) | EP3774914A2 (enExample) |
| JP (2) | JP2021521275A (enExample) |
| KR (1) | KR20200143436A (enExample) |
| CN (3) | CN113817066A (enExample) |
| AU (2) | AU2019252970A1 (enExample) |
| BR (1) | BR112020020828A2 (enExample) |
| CA (1) | CA3095373A1 (enExample) |
| CL (2) | CL2020002625A1 (enExample) |
| CO (1) | CO2020014167A2 (enExample) |
| CR (1) | CR20200549A (enExample) |
| IL (1) | IL277925A (enExample) |
| MA (1) | MA52227A (enExample) |
| MX (1) | MX2020010728A (enExample) |
| PE (1) | PE20201346A1 (enExample) |
| PH (1) | PH12020551664B1 (enExample) |
| RU (1) | RU2022105827A (enExample) |
| SG (1) | SG11202010064QA (enExample) |
| TW (1) | TW202012441A (enExample) |
| WO (1) | WO2019198051A2 (enExample) |
| ZA (1) | ZA202006325B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220396635A1 (en) * | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| US12698331B2 (en) | 2019-12-10 | 2026-08-04 | Institut Pasteur | Antibody blocking human FcγRIIIA and FcγRIIIB |
| GB201919058D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| EP4545569A3 (en) * | 2020-06-30 | 2025-10-08 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| TW202233248A (zh) * | 2020-11-08 | 2022-09-01 | 美商西健公司 | 組合療法 |
| MX2023006573A (es) * | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
| US20240101677A1 (en) * | 2021-01-27 | 2024-03-28 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
| JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| US20250206823A1 (en) * | 2021-07-30 | 2025-06-26 | Qure Biotechnology (Shanghai) Co., Ltd. | Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| CA3233085A1 (en) * | 2021-09-24 | 2023-03-30 | Synergy Imt, Inc. | Composition of recombinant antigen binding molecules and method of making and using thereof |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| CN114349869B (zh) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | 一种双特异性的nk细胞激动剂及制备方法和应用 |
| JP2025528087A (ja) * | 2022-08-05 | 2025-08-26 | チマゲン・バイオサイエンシズ，リミテッド | 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体 |
| AU2023343472A1 (en) * | 2022-09-14 | 2025-03-20 | Otsuka Pharmaceutical Co., Ltd. | Pd-1 agonist antibodies |
| JP2026504499A (ja) * | 2023-02-06 | 2026-02-05 | レプ バイオファーマ カンパニー， リミテッド | 抗ｃｄ１６ａ抗体およびその使用 |
| KR20240136856A (ko) * | 2023-03-06 | 2024-09-19 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-cd16 항체 및 이의 용도 |
| WO2025257588A1 (en) * | 2024-06-10 | 2025-12-18 | Affimed Gmbh | Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance |
| WO2026087751A1 (en) | 2024-10-24 | 2026-04-30 | Affimed Gmbh | Combination of immune cell engager and nk cell products |
| WO2026101948A1 (en) * | 2024-11-05 | 2026-05-15 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP4751777A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor |
| EP4751731A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane |
| EP4751734A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Bispecific antibody construct dosage regimen for treating nsclc |
| CN121362261A (zh) * | 2025-10-30 | 2026-01-20 | 北京再青生物科技有限公司 | 一种靶向T细胞及Her2的双特异性抗体并串联IL-15及其受体的融合蛋白及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| LT2361936T (lt) * | 2010-02-25 | 2016-09-12 | Affimed Gmbh | Antigeną rišanti molekulė ir jos panaudojimas |
| EP2714737A1 (en) | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
| WO2014006217A1 (en) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EP2970485A1 (en) * | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EP3091031A1 (en) * | 2015-05-04 | 2016-11-09 | Affimed GmbH | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| CA2983706C (en) * | 2015-05-04 | 2024-01-02 | Affimed Gmbh | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| WO2018158349A1 (en) * | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
-
2019
- 2019-04-12 EP EP19725409.7A patent/EP3774914A2/en active Pending
- 2019-04-12 CN CN202111125475.XA patent/CN113817066A/zh active Pending
- 2019-04-12 MA MA052227A patent/MA52227A/fr unknown
- 2019-04-12 SG SG11202010064QA patent/SG11202010064QA/en unknown
- 2019-04-12 CN CN201980033176.8A patent/CN112119097B/zh active Active
- 2019-04-12 PE PE2020001584A patent/PE20201346A1/es unknown
- 2019-04-12 CR CR20200549A patent/CR20200549A/es unknown
- 2019-04-12 PH PH1/2020/551664A patent/PH12020551664B1/en unknown
- 2019-04-12 MX MX2020010728A patent/MX2020010728A/es unknown
- 2019-04-12 WO PCT/IB2019/053040 patent/WO2019198051A2/en not_active Ceased
- 2019-04-12 CA CA3095373A patent/CA3095373A1/en active Pending
- 2019-04-12 RU RU2022105827A patent/RU2022105827A/ru unknown
- 2019-04-12 CN CN202111125559.3A patent/CN113880952A/zh active Pending
- 2019-04-12 JP JP2021504593A patent/JP2021521275A/ja active Pending
- 2019-04-12 KR KR1020207032435A patent/KR20200143436A/ko not_active Ceased
- 2019-04-12 AU AU2019252970A patent/AU2019252970A1/en not_active Abandoned
- 2019-04-12 BR BR112020020828-0A patent/BR112020020828A2/pt not_active IP Right Cessation
- 2019-04-15 TW TW108113068A patent/TW202012441A/zh unknown
- 2019-12-13 US US16/714,396 patent/US11001633B2/en active Active
-
2020
- 2020-10-09 CL CL2020002625A patent/CL2020002625A1/es unknown
- 2020-10-11 IL IL277925A patent/IL277925A/en unknown
- 2020-10-12 ZA ZA2020/06325A patent/ZA202006325B/en unknown
- 2020-11-12 CO CONC2020/0014167A patent/CO2020014167A2/es unknown
-
2021
- 2021-04-20 US US17/235,854 patent/US20210253698A1/en not_active Abandoned
-
2023
- 2023-04-14 CL CL2023001085A patent/CL2023001085A1/es unknown
-
2024
- 2024-04-17 US US18/637,556 patent/US20240294647A1/en active Pending
-
2025
- 2025-01-17 JP JP2025006634A patent/JP2025081307A/ja active Pending
-
2026
- 2026-01-27 AU AU2026200541A patent/AU2026200541A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200109202A1 (en) | 2020-04-09 |
| WO2019198051A3 (en) | 2019-11-14 |
| CL2023001085A1 (es) | 2023-10-06 |
| JP2025081307A (ja) | 2025-05-27 |
| PH12020551664A1 (en) | 2021-12-13 |
| US20240294647A1 (en) | 2024-09-05 |
| CN112119097B (zh) | 2021-10-15 |
| CR20200549A (es) | 2021-03-18 |
| CN113880952A (zh) | 2022-01-04 |
| CO2020014167A2 (es) | 2021-04-08 |
| MX2020010728A (es) | 2020-11-06 |
| EP3774914A2 (en) | 2021-02-17 |
| SG11202010064QA (en) | 2020-11-27 |
| IL277925A (en) | 2020-11-30 |
| TW202012441A (zh) | 2020-04-01 |
| US11001633B2 (en) | 2021-05-11 |
| US20210253698A1 (en) | 2021-08-19 |
| AU2019252970A1 (en) | 2020-11-26 |
| JP2021521275A (ja) | 2021-08-26 |
| PH12020551664B1 (en) | 2023-05-19 |
| MA52227A (fr) | 2021-04-21 |
| AU2026200541A1 (en) | 2026-02-19 |
| CN113817066A (zh) | 2021-12-21 |
| CA3095373A1 (en) | 2019-10-17 |
| ZA202006325B (en) | 2025-12-17 |
| CN112119097A (zh) | 2020-12-22 |
| WO2019198051A2 (en) | 2019-10-17 |
| CL2020002625A1 (es) | 2021-02-19 |
| KR20200143436A (ko) | 2020-12-23 |
| RU2022105827A (ru) | 2022-04-05 |
| BR112020020828A2 (pt) | 2021-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014167A2 (es) | Constructos de fusión de anticuerpos que se acoplan a células | |
| MX2022016192A (es) | Anticuerpos anti-nectina-4 condicionalmente activos. | |
| MX2022006758A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| CO2019003945A2 (es) | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1 | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| MX2018013738A (es) | Anticuerpos que comprenden dominios constantes quimericos. | |
| CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| MX2020013631A (es) | Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas. | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| CL2009000441A1 (es) | Metodo para modificar el punto isoelectrico (pl) de un péptido que comprende una region variable de un anticuerpo mediante la sustitucion de aminoacidos en la region cdr, anticuerpos que tiene un pl modificados en las regiones cdr, util para aumentar el tiempo de residencia en el plasma. | |
| WO2014144542A3 (en) | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| ES2684475T3 (es) | Proteínas que se unen a beta amiloide | |
| MX2021000788A (es) | Composiciones de anticuerpos del receptor de fc (fcrn). | |
| AR114102A1 (es) | Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación | |
| EA201691795A1 (ru) | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина | |
| MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| PE20100695A1 (es) | Proteina vegetal hibrida y metodo para obtener la misma | |
| EA201990822A1 (ru) | Иммуномодулирующие слитые белки | |
| EA202090838A1 (ru) | Иммуномодулирующие слитые белки |